Zydus Lifesciences Share Price

Pharmaceuticals company Zydus Lifesciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Total Revenue from Operations: For Q4FY26, revenue stood at Rs 75,870 million, reflecting a YoY growth of 16.22% from Rs 65,279 million in Q4FY25 and a QoQ growth of 10.53% from Rs 68,645 million in Q3FY26. For the full year FY26, revenue reached Rs 271,484 million compared to Rs 232,415 million in FY25. Total Income: Total income for Q4FY26 was Rs 77,212 million, representing a YoY increase of 16.84% from Rs 66,085 million and a QoQ increase of 10.68% from Rs 69,759 million. The annual total income for FY26 was Rs 276,579 million. Profit Before Tax (before exceptional items and share of profit of joint ventures): For Q4FY26, profit stood at Rs 20,572 million, showing a YoY growth of 8.75% compared to Rs 18,916 million and a QoQ growth of 43.03% from Rs 14,383 million. Net Profit for the Period/Year: Net profit for Q4FY26 was Rs 12,725 million, a YoY growth of 8.68% from Rs 11,709 million and a QoQ growth of 22.11% from Rs 10,421 million. For the full year FY26, net profit was Rs 50,400 million, up 11.37% from Rs 45,255 million in FY25. Earnings Per Share (EPS): Basic and diluted EPS for FY26 stood at Rs 50.09, compared to Rs 44.97 in FY25. Standalone Financial Highlights: Total Income: Standalone total income for Q4FY26 was Rs 42,360 million, representing a YoY decrease of 29.46% from Rs 60,050 million and a QoQ growth of 53.62% from Rs 27,574 million. Annual total income for FY26 was Rs 131,515 million. Total Revenue from Operations: For Q4FY26, standalone revenue stood at Rs 37,409 million, showing a YoY decrease of 35.72% from Rs 58,196 million and a QoQ growth of 63.81% from Rs 22,836 million. Net Profit for the Period/Year: Net profit for Q4FY26 was Rs 17,220 million, down 38.80% YoY from Rs 28,137 million but up 480.78% QoQ from Rs 2,965 million. Annual net profit for FY26 was Rs 35,598 million. Business Highlights: Segment-wise Performance Pharmaceuticals: FY26 segment revenue reached Rs 224,121 million, compared to Rs 205,415 million in FY25. Consumer Products: FY26 segment revenue reached Rs 39,540 million, compared to Rs 26,976 million in FY25. Medical Technologies: FY26 segment revenue reached Rs 7,823 million, compared to Rs 24 million in FY25. Settlement and License Agreement: Zydus Pharmaceuticals USA, Inc. and Zydus Lifesciences Limited entered into a settlement with Astellas Pharma Inc. regarding Myrbetriq, paying a one-time settlement cost of Rs 3,975 million (USD 45 million). Strategic Acquisitions: Zydus MedTech (France) SAS acquired 100% share capital of Amplitude Surgical SA, France. Alidac UK Limited, a subsidiary of Zydus Wellness Limited, acquired Comfort Click Limited for GBP 239 million plus a GBP 2.64 million profit ticker. Zylidac Bio LLC completed the acquisition of biologics manufacturing facilities from Agenus Inc., USA, for USD 75 million upfront. New Labour Codes: The estimated one-time financial impact resulting in an increase in gratuity and leave encashment liability was Rs 601 million for Zydus Standalone and Rs 849 million for the Zydus Group. Dividend: The Board of Zydus Lifesciences Limited has recommended a final dividend of Rs 1/- (@100%) per equity share of face value Re 1/- each for FY26. Sharvil Patel, Managing Director - Zydus Lifesciences, said: We closed FY26 on a strong note, delivering on our commitments —both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near -term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further. Result PDF

• Trendlyne
• 1 week 5 days ago

Pharmaceuticals company Zydus Lifesciences announced Q3FY26 results Revenue from operations at Rs 68,645 million, up 30 % over last year. Research & Development (R&D;) investments for the quarter stood at Rs 6,074 million (8.8 % of revenues). EBITDA for the quarter was Rs 18,164 million, up 31% YoY. EBITDA margin for the quarter stood at 26.5 %, which is an improvement of 20 bps on a YoY basis. Net Profit (Adjusted) for the quarter was Rs 11,109 million, up 9% YoY. Capex (organic) for the quarter was Rs 4,637 million. Sharvil Patel, Managing Director - Zydus Lifesciences, said: "Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A; and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation. Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value." Result PDF

• Trendlyne
• 3 months 2 weeks ago

Pharmaceuticals company Zydus Lifesciences announced Q2FY26 results Revenue from operations at Rs 61,232 million, up 17% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 4,820 million (7.9% of revenues). EBITDA for the quarter was Rs 20,158 million, up 38% YoY. EBITDA margin for the quarter stood at 32.9%, which is an improvementof 500 bps on a YoY basis. Net Profit for the quarter was Rs 12,586 million, up 38% YoY. Capex (organic) for the quarter was Rs 4,911 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said: Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals. We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech. These results reflect our commitment to sustainable growth and global expansion, anchored in quality, compliance, and patient-centric innovation. Result PDF

• Trendlyne
• 6 months 3 weeks ago